Healthcare investor with over 20 years of investment and operating experience.In 2019, Linda co-founded Avestria Ventures to invest in early-stage women's health and female-led life science ventures. Previously, as a partner at LMN Ventures, Linda invested in early-stage health and wellness companies. Whether as an institutional investor, a corporate M&A executive, a hedge fund analyst or a private venture investor, Linda has invested in public and private life science companies most of her career. As a member of private investment partnerships, including Tudor Investments and Essex Investment Management, she invested over $3.2 billion of equity capital, including $1.1 billion of performance-based hedge funds. She also built profitable equity research franchises in healthcare services at both Banc of America Securities and Pacific Growth Equities, successfully raising over $1.8 billion of capital for public companies. Linda’s corporate investment experience includes leading M&A at both Novartis Diagnostics and Applied Biosystems where her transactions included the $5.1 billion cash and stock sale of ABI to Life Technologies Corp. in 2008. She has held corporate development and finance roles at a number of venture-backed life science companies, including VitaPath Genetics, Singulex, Raindance Technologies (sold to Bio-Rad), and Linkage Biosciences (sold to Thermo Fisher).